Media Releases

02 May 2025
Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders
30 Apr 2025
Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset
29 Apr 2025
New data with daridorexant assessing the transition from night to day in insomnia disorder published in Sleep Medicine
16 Apr 2025
Higher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond
09 Apr 2025
The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension
09 Apr 2025
US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement
27 Mar 2025
Idorsia publishes its Annual Report 2024
17 Mar 2025
US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients
14 Mar 2025
Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia
04 Mar 2025
Idorsia announces financial results for 2024
26 Feb 2025
Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations
26 Feb 2025
Idorsia and Viatris update their collaboration for selatogrel and cenerimod
26 Feb 2025
Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties
25 Feb 2025
Bondholders approve amended terms of the 2025 convertible bonds
12 Feb 2025
Idorsia publishes the resolutions for the upcoming bondholder meeting
15 Jan 2025
Idorsia presents at J.P. Morgan Healthcare Conference 2025 – fighting to create value for all stakeholders
14 Jan 2025
Idorsia publishes an invitation to a bondholder meeting
13 Jan 2025
Idorsia to call for a bondholder meeting
20 Dec 2024
Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan
27 Nov 2024
Idorsia enters into exclusive negotiations for global rights to aprocitentan

Ad hoc announcements pursuant to Art. 53 LR

Ad hoc announcements pursuant to Art. 53 LR have been classified from 2021 onwards. A full archive of press releases can be found under the "All" tab.